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Summary
Sialic acid-binding immunoglobulin-like lectin (Siglec)-15 has recently been identi-
fied as a critical tumour checkpoint, augmenting the expression and function of
programmed death-ligand 1. We raised a monoclonal antibody, A9E8, specific for
Siglec-15 using phage display. A9E8 stained myeloid leukaemia cell lines and
peripheral cluster of differentiation (CD)33+ blasts and CD34+ leukaemia stem cells
from patients with acute myeloid leukaemia (AML). By contrast, there was minimal
expression on healthy donor leucocytes or CD34+ stem cells from non-AML donors,
suggesting targeting Siglec-15 may have significant therapeutic advantages over its
fellow Siglec CD33. After binding, A9E8 was rapidly internalised (half-life of 180 s)
into K562 cells. Antibodies to Siglec-15 therefore hold therapeutic potential for
AML treatment.
Keywords: Siglec-15, acute myeloid leukaemia, antibody, phage display, en-
docytosis.
Introduction
Acute myeloid leukaemia (AML) is a significant health bur-
den with an incidence of around four cases/100 000/year1
with ~3000 cases/year in the UK. Curative treatment is inten-
sive, arduous for the patient, and requires long hospital
admissions. In contrast to other malignancies, immunothera-
peutic agents are yet to play a major role in treatment.
Identifying suitable tumour-specific antigens is a major
barrier in developing immunotherapies.2 In AML, the most
promising target has been the sialic acid-binding
immunoglobulin-like lectin (Siglec), cluster of differentiation
(CD)33, which is targeted by gemtuzumab ozogamicin (GO,
Mylotarg) a toxin-(calicheamicin) conjugated antibody.3
Despite setbacks, a randomised trial of 237 patients aged
≥60 years and ineligible for intensive chemotherapy showed
an improved overall survival (hazard ratio 069) in those
assigned to GO induction and consolidation compared with
best supportive care.4
Sialic acids are nine carbon-based sugars found at the ter-
mini of most mammalian glycan structures. The Siglecs are
immunoglobulin superfamily receptors that bind to sialic
acids and are commonly expressed on immune cells, particu-
larly of the myeloid lineage.5 Most Siglecs are inhibitory, but
some are activating, namely Siglecs-14, -15 and -16.6,7 A
rapidly evolving sub-family of Siglecs, known as the CD33-
related (CD33r) Siglecs, demonstrate potential as AML
targets.8
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Siglec-15 is a new member of the Siglec family primarily
expressed on a subset of myeloid cells.6 Siglec-15 has also
been shown to bind the tumour antigen sialyl-Thomsen-nou-
velle antigen (sTn).6 Siglec-15 is unusual in that it is
equipped with both negative and positive signalling motifs.6
Siglec-15 contains a lysine residue in the transmembrane that
potentially mediates association with signalling adaptor mole-
cules, such as DNAX-activating protein 10 (DAP10), DAP12
and the Fc receptor common c (FcRc) chain, to promote
cellular activation, yet also contains a cytoplasmic
immunoreceptor tyrosine-based inhibitory motif (ITIM)-like
motif known as immunoreceptor-tyrosine based switch motif
(ITSM) that generally mediates inhibitory signals.9 In sup-
port of this, Siglec-15 has recently been identified as a novel
check point inhibitor with mutually exclusive expression to
the classical checkpoint inhibitor, programmed death-ligand
1 (PD-L1), suggesting antibodies to Siglec-15 may have a role
as immune checkpoints that can complement PD-L1 inhibi-
tors.10
In the present study, we developed a monoclonal antibody
(A9E8) to Siglec-15 using phage display. We show that A9E8
stains Siglec-15 on CD33+ peripheral blood monocytic cells
from patients with AML but not from healthy donors. A9E8
also stains CD34+ leukaemic stem cells (LSCs) in AML, but
not equivalent CD34+ cells from non-AML donors. Finally,
A9E8 induces the rapid internalisation of Siglec-15 on mye-
loid leukaemia cells, such as K562, suggesting therapeutic
potential for AML treatment.
Results
Generation of Siglec-15 specific antibody, A9E8
Phage display was employed to select a specific antibody,
A9E8, against Siglec-15 (Figure S1), which binds to overex-
pressed cell surface Siglec-15 as well as endogenous Siglec-15
from leukaemia cell lines such as K562 (Figure S2; Figure S3).
Clustered regularly interspaced short palindromic repeats
(CRISPR) deletion of SIGLEC15 from the cell-line K562
resulted in loss of A9E8 staining (Figure S1D). Enhanced
surface expression of full length Siglec-15 (N-terminal FLAG-
tagged) was observed when paired with clones stably express-
ing DAP10, DAP12 and FcRc (Figure S4).
Absence of Siglec-15 surface expression on peripheral
blood leucocytes from healthy donors
Siglec-15 is absent on the surface of most mature leucocytes
from healthy donors: T cells (02% CD3+), B cells (02%
CD19+) and natural killer cells (03% CD3CD56+), but a
small (~08%) proportion of monocytes (CD14+) showed
Siglec-15 surface expression (Figure S5A). The overall nega-
tive staining of mature circulating leucocytes was confirmed
on nine healthy donors (Fig 1D). We report very weak
Siglec-15 surface expression on 7% of cultured macrophages
derived from peripheral blood monocytes and extremely low
Siglec-15 surface expression on ~4% of dendritic cells before
lipopolysaccharide (LPS) stimulation (Figure S5B), both of
which were lost following 24 h of LPS stimulation (Fig-
ure S5B). These results show that in healthy donors, expres-
sion of Siglec-15 is low or absent on the cell surfaces of most
mature circulating leucocytes as well as in vitro cultured
macrophages and dendritic cells.
Siglec-15 is a prominent surface antigen on circulating
myeloid blasts
In contrast, significantly higher Siglec-15 surface expression
was found on peripheral blood cells from nine of the 12
patients with AML tested (Fig 1A–D), with an average of
~18% of the subpopulation being Siglec-15 positive as com-
pared to only 06% for circulating peripheral blood mononu-
clear cells (PBMCs) from healthy donors (Fig 1D). CD33
and Siglec-15 show comparable level of percentage expression
on circulating leucocytes (Fig 1E), giving a strong correlation
(Pearson’s correlation r = 09823, n = 12) (Fig 1E). Three of
the patients with AML were profiled in detail, where we see
consistent co-expression of Siglec-15 with CD14 (Fig 1A–C).
CD33 has been reported to be expressed on 90% of AML
blasts.11 Surprisingly, we identified one AML patient amongst
the 12, patient B (Fig 1B), who was CD33-negative,
expressed a significant level of Siglec-15 on 20% of the
peripheral cells. The strong correlation between Siglec-15 and
CD33, as well as the existence of CD33-Siglec-15+ pheno-
types is supported by public data found in Figure S6. The
overall A9E8 binding specificity to circulating AML leuco-
cytes over healthy cells is also reflected in the fluorescence
intensities (Fig 1F). These data indicate that Siglec-15 is
expressed on significantly higher percentage of circulating
leucocytes in patients with AML than in healthy donors.
A9E8 induces a rapid internalisation of Siglec-15 from
the cell surface
A fast rate of Siglec-15 internalisation would be advantageous
for toxin-conjugated antibody targeting of Siglec-15-positive
AML blasts. Rapid internalisation of Siglec-15 is expected
from its cytoplasmic ITSM motif (sequence: SNYENL), con-
forming to the classical endocytosis YxxФ motif (X, any
amino acid; Ф, hydrophobic residue).12 Extremely rapid
endocytosis of Siglec-15 was noted on K562 cell line through
cross-linking of A9E8 with a half-life of only 174 s (Fig 2A).
A9E8 does not induce endocytosis if Siglec-15 lacking its
cytoplasmic tail (Fig 2B), indicating the observed phe-
nomenon cannot be explained by dissociation of the A9E8
antibody from the cell surface. Rapid endocytosis is also
observed in AML peripheral blood samples (Fig 2C), consis-
tent with K562 cell line and an AML cell line, U937 (Fig-
ure S7). Z-stack confocal microscopy showed the presence of
A9E8 antibody in permeabilised K562 cells (Fig 2D, Ei-v).
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Circulating peripheral cells from non-AML patients but
who have had granulocyte-colony stimulating factor (G-CSF)
mobilisation showed no A9E8 staining (Figure S8A,B). These
peripheral cells offer a higher representation of progenitor
cells, including CD34+ stem cells (Figure S8A). These data
provide support for the specificity of the A9E8 antibody in
AML bone marrows, as healthy CD34+ stem cells would not
be targeted. Furthermore, CD34+CD38 subpopulations of
circulating peripheral cells from four AML and three non-
AML G-CSF-treated patients were compared (Figure S8C–E).
This so-called leukaemic stem cells (LSCs) compartment
appears to have high levels of Siglec-15 expression in AML,
but not in non-AML equivalents (Figure S8C–E).
Discussion
We used phage display to develop an antibody, A9E8, speci-
fic for Siglec-15 and observed expression on circulating cells
in patients with AML with contrasting low/negligible expres-
sion on healthy cells. The antibody also induced rapid endo-
cytosis, with a half-life of 3 min compared to >100 min for
Siglec-5 and -9.8 These properties support A9E8 as a poten-
tial novel therapeutic agent for the treatment of AML.
CD33 is expressed on monocytes and macrophages of
healthy individuals. Due to the relatively low expression of
Siglec-15 on mature myeloid cells, A9E8 has the potential to
be associated with less myelosuppression than GO.5,13 We
Fig 1. High sialic acid-binding immunoglobulin-like lectin (Siglec)-15 surface expression on circulating blood cells from patients with acute mye-
loid leukaemia (AML). Cell surface expression of Siglec-15 on peripheral blood leucocyte preparations from the peripheral blood of patients with
AML. Nine out of 12 patients with AML showed significant cell surface expression of Siglec-15 compared to healthy peripheral blood leucocytes.
(A) Representative plots from ‘Patient A’ showing high levels of cell-surface Siglec-15 expression on AML blasts [36% of all peripheral blood
mononuclear cells (PBMCs)]. Siglec-15 is co-expressed with CD14 and human leucocyte antigen-DR isotype (HLA-DR). Negative control: mouse
immunoglobulin G1 (IgG1) isotype antibody. (B) Representative plots (left panels) from ‘Patient B’ showing negative cell surface staining for
CD33 on AML blasts, although 20% of blasts are positive for Siglec-15. Histograms (right panels) comparing cell surface expression of CD33 and
Siglec-15 on AML blasts from ‘Patient B’ (isotype control staining, filled histograms; anti-CD33/Siglec-15 antibody staining, open histograms).
(C) Representative plots from ‘Patient C’ showing 10% of AML blasts express Siglec-15 on the cell surface, most of which were
CD33+CD14+HLA-DR. (D) Percentage of total circulating PBMCs expressing cell-surface Siglec-15 from 14 patients with AML (open circles)
and nine healthy donors (solid squares). Normalised percentage positive expression shown. Mann–Whitney two-tailed t-test, median and
interquartile ranges are indicated (***P = 00002). (E) Correlation between normalised percentage Siglec-15+ and CD33+ populations from 10
patients with AML. Pearson’s correlation: r = 09354, P < 00001, two tailed test. (F) Geometric mean of fluorescence intensity (gMFI) values of
A9E8 binding normalised against isotype binding for PBMCs expressing cell-surface Siglec-15 from 12 patients with AML (open circles) and 12
healthy donors (solid squares). Mann–Whitney two-tailed t-test, median and interquartile ranges are indicated (***P = 00002). [Colour figure
can be viewed at wileyonlinelibrary.com]
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found that in one case of CD33 AML, there was significant
expression of Siglec-15, suggesting that Siglec-15 may be a
viable target on blasts that lack CD33.5,13,14 While a potential
toxin-conjugated A9E8 may target some osteoclasts that
express Siglec-15, depletion of Siglec-15+ osteoclasts may
provide the benefit of preventing bone-loss in AML disease
and AML metastasis to bone.15
Collectively, our present data demonstrate A9E8 is specific
for AML blasts and LSCs, but not healthy cells, and induces
rapid Siglec-15 internalisation on the K562 myeloid
leukaemia cell line. A9E8 is therefore a promising antibody
for targeting conjugated toxins to AML blasts and the LSC
compartment. Further characterisation of the expression pat-
tern of Siglec-15 on haematopoietic cells from patients with
AML and healthy donors should be undertaken.
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